SST and gastric cancer: Consistent with a role of somatostatin and its receptors in reducing the angiogenic process by acting at both, the endothelial cells and the tumoral cells levels [30], the use of SSAs in clinical trials has revealed that somatostatin could exert its anti-vasculogenesis effect by downregulating the serum VEGFs and, therefore, can be used as an important adjuvant to improve the survival of gastric cancer patients [26].